Alpha Cognition Inc. reported its financial results for the third quarter ended September 30, 2024. The company announced a net loss of $(1,859,906) for the quarter, which represents a significant improvement compared to a net loss of $(3,280,355) for the same period in 2023.
Diluted earnings per share for Q3 2024 were $(0.31), an improvement from $(0.84) in Q3 2023. For the nine months ended September 30, 2024, the net loss was $(8,978,129), with diluted EPS of $(1.51).
The company highlighted the FDA approval of ZUNVEYL as an important breakthrough for Alzheimer’s patients and stated its focus on commercial preparation in the U.S. market and ex-U.S. licensing opportunities to bring this therapy to market in Q1 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.